A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
Public ClinicalTrials.gov record NCT02107703. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Study identification
- NCT ID
- NCT02107703
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 669 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 21, 2014
- Primary completion
- Feb 13, 2017
- Completion
- Nov 30, 2027
- Last update posted
- Oct 20, 2025
2014 – 2027
United States locations
- U.S. sites
- 43
- U.S. states
- 20
- U.S. cities
- 39
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| St. Bernards Medical Center | Jonesboro | Arkansas | 72401 | — |
| Highlands Oncology Group | Springdale | Arkansas | 72762 | — |
| University of California - San Diego | La Jolla | California | 92037-0845 | — |
| Kaiser Permanente | Riverside | California | 92505 | — |
| Univ of California San Francisco | San Francisco | California | 94115 | — |
| Stanford University Clinic | Stanford | California | 94305 | — |
| Palm Beach Cancer Institue | Atlantis | Florida | 33462 | — |
| Holy Cross Hospital | Fort Lauderdale | Florida | 33308 | — |
| Florida Cancer Specialists - South | Fort Myers | Florida | 33901 | — |
| Palm Beach Cancer Institue | Palm Beach Gardens | Florida | 33410 | — |
| Florida Cancer Specialists - North | St. Petersburg | Florida | 33705 | — |
| Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center | Tampa | Florida | 33612 | — |
| Palm Beach Cancer Institue | Wellington | Florida | 33414 | — |
| Palm Beach Cancer Institue | West Palm Beach | Florida | 33401 | — |
| University Cancer & Blood Center, LLC | Athens | Georgia | 30607 | — |
| Harbin Clinic | Rome | Georgia | 30165 | — |
| Quincy Medical Group | Quincy | Illinois | 62301 | — |
| Pharmasite Research, Inc. | Baltimore | Maryland | 21208 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Breslin Cancer Center | Lansing | Michigan | 48910 | — |
| Minnesota Oncology/Hematology PA | Minneapolis | Minnesota | 55404 | — |
| Washington University Medical School | City of Saint Peters | Missouri | 63376 | — |
| Washington University Medical School | Creve Coeur | Missouri | 63141 | — |
| Freeman Cancer Institute | Joplin | Missouri | 64804 | — |
| St Lukes Hospital | Kansas City | Missouri | 64111 | — |
| Washington University Medical School | St Louis | Missouri | 63110 | — |
| Washington University Medical School | St Louis | Missouri | 63129 | — |
| Billings Clinic | Billings | Montana | 59101 | — |
| Dartmouth-Hitchcock Medical Center | Lebanon | New Hampshire | 03756-0001 | — |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Rochester General Hospital | Rochester | New York | 14621 | — |
| Rochester General Hospital | Rochester | New York | 14625 | — |
| Novant Health, Oncology Research Institute | Winston-Salem | North Carolina | 27103 | — |
| Oklahoma Cancer Specialists & Research Institute, LLC | Tulsa | Oklahoma | 74146 | — |
| Sanford Research/USD | Sioux Falls | South Dakota | 57104 | — |
| The Boston Baskin Cancer Group | Memphis | Tennessee | 38120 | — |
| SMO Sarah Cannon Research Inst. | Nashville | Tennessee | 37203 | — |
| Baylor College of Medicine | Houston | Texas | 77030 | — |
| Oncology Consultants P.A. | Houston | Texas | 77030 | — |
| Utah Cancer Specialists | Salt Lake City | Utah | 84106 | — |
| Kadlec Clinic Hematology and Oncology | Kennewick | Washington | 99336 | — |
| St Mary Regional Cancer Center | Walla Walla | Washington | 99362 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 103 non-U.S. sites.
Recently updated Breast Neoplasms trials
Other public records listing Breast Neoplasms. Sorted by last update posted; newest first. Not a recommendation.
- NCT07748377: Increasing Breast and Colorectal Cancer Screening in the Community Not yet recruiting
- NCT07038369: A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations Active, not recruiting
- NCT02476786: Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score Recruiting
- NCT05607004: (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer Active, not recruiting
- NCT04641247: A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study Recruiting
- NCT04796220: Focused Ultrasound and Gemcitabine in Breast Cancer Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02107703, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 20, 2025 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02107703 live on ClinicalTrials.gov.